Roles of P2X7 receptor in glial and neuroblastoma cells: the therapeutic potential of P2X7 receptor antagonists.
Recently, one of the P2 purinergic receptors, the P2X(7) receptor, has been extensively studied in nervous system and important functions have been revealed in both astrocytes and microglia. Stimulation of the receptors induces a sustained and nondesensitized increase in intracellular Ca(2+) concentration ([Ca(2+)](i)). In astrocytes purinergic receptors primarily regulate neurotransmission by inducing gliotransmitters release whereas in microglia the receptors stimulate the processing and release of proinflammation cytokines such as interleukin-1 and are thereby involved in inflammation and neurodegeneration. Thus, P2X(7) receptors are considered not only to exert physiological functions but also mediate cell death. P2X(7) receptors have also been identified in various cancer cells and in neuroblastoma cells. In these cells, the P2X(7) receptor-mediated sustained Ca(2+) signal is important in maintaining cellular viability and growth. Accordingly, these findings not only lead to a better understanding of roles of the receptor but also prompt the development of more potent, selective and safer P2X(7) selective antagonists. These emerging antagonists bring new hope in the treatment of inflammatory-induced neurodegenerative diseases as well as neuroblastoma.
Sun
Synthia H
SH
Institute of Neuroscience, National Yang Ming University, Taipei, Taiwan, Republic of China. shsun@ym.edu.tw
D000818:Animals; D002118:Calcium / Q000378:metabolism; D016923:Cell Death / Q000502:physiology; D002454:Cell Differentiation; D002470:Cell Survival; D006801:Humans; D009447:Neuroblastoma / Q000378:metabolism*; D009457:Neuroglia / Q000378:metabolism*; D018377:Neurotransmitter Agents / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2 / Q000378:metabolism*; D058486:Receptors, Purinergic P2X7
D018377:Neurotransmitter Agents; C546468:P2RX7 protein, human; D020033:Protein Isoforms; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; D002118:Calcium
J Cell Physiol. 1989 Apr;139(1):109-15
2708449
J Neurosci. 2001 Sep 15;21(18):7143-52
11549725
J Neurochem. 1999 Jul;73(1):334-43
10386986
Development. 2005 Jun;132(12):2873-82
15930116
J Immunol. 1996 Feb 15;156(4):1531-9
8568257
J Pharmacol Exp Ther. 2006 Dec;319(3):1376-85
16982702
J Neurosci. 2006 Feb 1;26(5):1378-85
16452661
Br J Pharmacol. 2006 Dec;149(7):880-7
17031385
J Biol Chem. 1987 Jun 25;262(18):8884-8
3597398
J Biol Chem. 1993 Jul 25;268(21):15571-8
7687997
Br J Pharmacol. 2003 Oct;140(3):507-19
14522842
Trends Neurosci. 1990 Feb;13(2):43-6
1690928
Neuropharmacology. 1997 Sep;36(9):1295-301
9364484
J Neurosci. 2003 May 1;23(9):3588-96
12736329
Cancer Res. 2006 Jan 15;66(2):907-14
16424024
J Immunol. 2004 Mar 15;172(6):3399-405
15004138
J Neurosci. 2007 Aug 29;27(35):9525-33
17728465
Bioorg Med Chem Lett. 2003 Nov 17;13(22):4043-6
14592504
Neuroreport. 1996 Nov 4;7(15-17):2533-7
8981418
Eur J Pharmacol. 2006 Nov 21;550(1-3):1-7
17020759
J Neurochem. 2008 Apr;105(1):151-64
18067549
J Immunol. 2006 Apr 1;176(7):3877-83
16547218
Trends Pharmacol Sci. 1998 Mar;19(3):99-107
9584626
J Cell Sci. 2008 Nov 15;121(Pt 22):3717-28
18987356
Neuropharmacology. 1997 Sep;36(9):1285-94
9364483
Br J Pharmacol. 2007 Jul;151(5):571-9
17471177
J Biol Chem. 2001 Jan 5;276(1):125-32
11016935
Mol Pharmacol. 2000 Jul;58(1):82-8
10860929
Eur J Pharmacol. 2002 Jul 5;447(2-3):261-9
12151017
Am J Physiol Cell Physiol. 2003 Aug;285(2):C286-99
12660148
J Immunol. 2000 May 1;164(9):4893-8
10779799
Glia. 2002 Jan;37(1):8-18
11746779
Histopathology. 2004 Mar;44(3):206-15
14987223
Glia. 2009 Apr 15;57(6):622-33
18942742
J Neurochem. 1996 Oct;67(4):1694-701
8858955
J Biol Chem. 2002 Mar 22;277(12):10482-8
11790776
Annu Rev Pharmacol Toxicol. 1995;35:541-79
7598506
Curr Top Med Chem. 2004;4(16):1707-17
15579103
Nat Med. 2004 Aug;10(8):821-7
15258577
J Immunol. 1997 Aug 1;159(3):1451-8
9233643
Physiol Rev. 2002 Oct;82(4):1013-67
12270951
Blood. 2002 Jan 15;99(2):706-8
11781259
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13644-9
14597722
J Biol Chem. 1999 Nov 19;274(47):33206-8
10559192
J Neurochem. 2002 Oct;83(2):285-98
12423239
EMBO J. 2006 Nov 1;25(21):5071-82
17036048
J Neurosci. 2003 Feb 15;23(4):1320-8
12598620
Cell Signal. 2009 Jun;21(6):881-91
19385050
J Neurosci. 2002 Apr 15;22(8):3061-9
11943809
Bioorg Med Chem Lett. 2008 Mar 15;18(6):2089-92
18272366
J Neurochem. 2004 Jan;88(1):246-56
14675168
Trends Neurosci. 2003 Oct;26(10):536-42
14522146
FEBS J. 2009 Sep;276(18):5307-25
19682070
FEBS Lett. 2003 Mar 13;538(1-3):71-6
12633855
J Biol Chem. 1982 Mar 25;257(6):2834-41
6460764
Neuropharmacology. 1997 Sep;36(9):1127-39
9364468
J Pharmacol Exp Ther. 2008 Dec;327(3):620-33
18772321
Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12489-93
19666625
Science. 1996 May 3;272(5262):735-8
8614837